Efficacy of Prolonged Treatment With Pegylated Interferon (Peg-IFN) and Ribavirin in Thalassemic Patients With Hepatitis C Who Relapsed After Previous Peg-IFN-Based Therapy

Hepatitis Monthly
Saleh SandoughdaranMaryam Keshvari

Abstract

Most thalassemic patients with chronic hepatitis C virus (HCV) infection do not respond to therapy with pegylated interferon (Peg-IFN) plus ribavirin (RBV) due to hepatic siderosis and RBV dose reduction caused by RBV-induced anemia. In the present study, we recruited HCV genotype 1-infected thalassemic patients who had relapsed after a 48-week treatment with Peg-IFN plus RBV in order to evaluate the efficacy of a 72-week regimen of Peg-IFN plus RBV. In this retrospective study, 23 thalassemic patients with HCV genotype 1 infection who had prior relapse after treatment with Peg-IFN and RBV for 48 weeks were consecutively enrolled in this study for evaluation of the efficacy of a 72-week treatment regimen. For the 21 included cases, mean age was 29.7 years; 81% were men and 28.6% had cirrhosis. At the end of the treatment, nine (42.9%) patients had an undetectable level of HCV RNA in their sera. However, six months after treatment completion four of these patients relapsed and a sustained virological response (SVR) was found in five (23.8%) patients. Undetectable HCV RNA level at week 4 (P = 0.03) and undetectable HCV RNA level at week 12 (P < 0.01) were found to be predictors of SVR. There was an average 47.9% increase in blood...Continue Reading

References

Jul 14, 2001·Journal of Hepatology·H Van VlierberghUNKNOWN BASL Steering Committee
Nov 11, 2005·The American Journal of Gastroenterology·Ira M JacobsonBrian R Edlin
Apr 7, 2007·Journal of Pediatric Hematology/oncology·Hassan AbolghasemiHamid Hoorfar
Nov 30, 2007·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Brian L PearlmanSophia Saifee
Jun 17, 2008·Haematologica·Paul HarmatzUNKNOWN Thalassemia Clinical Research Network
Mar 18, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Bruce R BaconNorman Gitlin
Jun 23, 2009·Transfusion·Seyed-Moayed AlavianKamran Bagheri Lankarani
Nov 3, 2009·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Ashwani K SingalGagan K Sood
Nov 17, 2009·Gastroenterology·Peter FerenciUNKNOWN Austrian Hepatitis Study Group
Dec 6, 2011·Hepatitis Monthly·Seyed Moayed AlavianNastaran Mahboobi

❮ Previous
Next ❯

Citations

Jun 9, 2016·Hepatitis Monthly·Khashayar HesamizadehSeyed Moayed Alavian
Feb 9, 2016·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Masahiro ShinodaYuko Kitagawa
Apr 17, 2018·Journal of Clinical Laboratory Analysis·Seyed Ehsan AlavianAli Pouryasin
Jul 17, 2019·Journal of Cellular Biochemistry·Pratichi SinghFebin Prabhu Dass J

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.